Dr. Hoffman Discusses Challenges in Relapsed/Refractory Myeloma

James E. Hoffman, MD
Published: Friday, Apr 12, 2019



James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory multiple myeloma.

The biggest unmet need in this setting is two-fold, Hoffman says. These patients have already undergone intensive therapy, many of whom have undergone a stem cell transplant. These patients have a lot to recover from as their bodies have already been through a lot. Upon relapse, patients may not be fit enough to receive more therapy, explains Hoffman.

Relapsed/refractory myeloma is still in need of highly effective, minimally toxic therapeutic options. Myeloma is still incurable in 2019, so the field needs to continue moving toward curative strategies so that patients can receive a fixed duration of treatment. Currently, the disease is treated like a chronic illness where patients remain on therapy indefinitely. As such, there is a large physical, emotional, and financial burden on patients.
SELECTED
LANGUAGE


James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory multiple myeloma.

The biggest unmet need in this setting is two-fold, Hoffman says. These patients have already undergone intensive therapy, many of whom have undergone a stem cell transplant. These patients have a lot to recover from as their bodies have already been through a lot. Upon relapse, patients may not be fit enough to receive more therapy, explains Hoffman.

Relapsed/refractory myeloma is still in need of highly effective, minimally toxic therapeutic options. Myeloma is still incurable in 2019, so the field needs to continue moving toward curative strategies so that patients can receive a fixed duration of treatment. Currently, the disease is treated like a chronic illness where patients remain on therapy indefinitely. As such, there is a large physical, emotional, and financial burden on patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x